SCHEMBL19781804

SCHEMBL19781804

Cc1cc(OC(C)C)ccc1-c1ccc2ncc(-c3ccc(OC(C)C)cc3)n2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.42
CLK1 P49759 2/20 0.42
ACACB O00763 3/20 0.42
ACACA Q13085 3/20 0.42
DYRK1A Q13627 2/20 0.39
KCNH2 Q12809 1/20 0.39
FLT3 P36888 2/20 0.39
CYP1A2 P05177 1/20 0.38
TGFBR1 P36897 1/20 0.38
FYN P06241 1/20 0.38
PIK3CA P42336 2/20 0.38
MTOR P42345 2/20 0.38
RIPK2 O43353 1/20 0.37
WDR5 P61964 1/20 0.37
BCL2 P10415 1/20 0.37
MDM2 Q00987 1/20 0.37
MCL1 Q07820 1/20 0.37
MAP4K4 O95819 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781807 0.87 CLK1 (0.43) CLK1DYRK1AKCNH2FLT3CYP1A2
SCHEMBL19781539 0.85 CLK1 (0.47) SCN5ACLK1DYRK1AKCNH2FLT3
SCHEMBL19781160 0.84 FLT3 (0.43) CLK1ACACBACACADYRK1AFLT3
SCHEMBL19781810 0.82 KCNH2 (0.43) SCN5ACLK1DYRK1AKCNH2FLT3
SCHEMBL26361714 0.82 FLT3 (0.46) CLK1DYRK1AKCNH2FLT3CYP1A2
SCHEMBL19781609 0.80 PIK3CA (0.51) CLK1DYRK1AKCNH2FLT3CYP1A2
SCHEMBL19781166 0.80 KCNH2 (0.47) CLK1KCNH2FLT3CYP1A2TGFBR1
SCHEMBL24460212 0.79 PIK3CA (0.51) SCN5ACLK1DYRK1AKCNH2FLT3
SCHEMBL19781168 0.79 SCN5A (0.50) SCN5ACLK1DYRK1AKCNH2FLT3
SCHEMBL22032850 0.79 FLT3 (0.43) CLK1DYRK1AFLT3CYP1A2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R SCN5A 4401/4885CLK1 3537/4885ACACB 309/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S SCN5A 2389/4885CLK1 3012/4885ACACB 1961/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S SCN5A 2389/4885CLK1 3012/4885ACACB 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.